Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers

Carcinomas of the oesophagus, stomach, pancreas and liver are common and account for a disproportionately high number of cancer deaths. There is a need for new treatment options for patients with advanced disease. Immunomodulatory treatments including immune checkpoint blockade offer a promising new...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2018-10, Vol.52 (Pt 2), p.241-252
Main Authors: Lee, Belinda, Hutchinson, Ryan, Wong, Hui-Li, Tie, Jeanne, Putoczki, Tracy, Tran, Ben, Gibbs, Peter, Christie, Michael
Format: Article
Language:English
Subjects:
Animals
Biomarkers
Biomarkers, Tumor - immunology
Gastric
Hepatocellular
Humans
Immunomodulation - immunology
Immunotherapy
Immunotherapy - methods
Neoplasms - immunology
Neoplasms - therapy
Pancreas
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carcinomas of the oesophagus, stomach, pancreas and liver are common and account for a disproportionately high number of cancer deaths. There is a need for new treatment options for patients with advanced disease. Immunomodulatory treatments including immune checkpoint blockade offer a promising new approach, with efficacy shown in other solid tumour types. However, only a small proportion of patients with carcinomas of the oesophagus, stomach, pancreas and liver have responded to single agent checkpoint inhibitors, and there is a need for markers that are predictive of response to guide treatment of individual patients. Predictive markers may include epidemiological factors such as ethnicity, the genomic status of the tumour, circulating markers, expression of immune checkpoint molecules, and other features of the stromal/immune response at the site of the tumour. This review will focus on predictive biomarkers for immune checkpoint blockade in oesophageal, gastric, pancreatic and hepatocellular carcinomas, including the genomic context and immune landscape in which they occur. Pancreatic carcinomas are largely resistant to immune checkpoint inhibition in trials to date, therefore emerging immunomodulatory treatments in this tumour type are also reviewed.
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2017.12.009